NCT07109401View on ClinicalTrials.gov

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

December 31, 2028

Conditions
Perioperative ImmunotherapyLimited Stage Lung Small Cell CarcinomaResectable Small Cell Lung Cancer
Interventions
DRUG

Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

Neoadjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide; Adjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER